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Stimulation of mast cells through their high afﬁnity IgE receptor (FceRI) leads to the secretion of
pre- and neoformed soluble mediators through vesicular carriers. This process is highly regulated
in order to adapt the secretion of these potentially dangerous factors to the physiological needs. This
regulation requires numerous essential effectors that are necessary to transmit the initial signal of
FceRI aggregation and couple it to the sophisticated secretory machinery of membrane fusion. Stud-
ies in recent years have led to the discovery of a series of new effector molecules that link FceRI to
secretion. We describe here some of the new developments that have allowed to obtain a clearer pic-
ture of stimulus/secretion coupling in mast cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Control of degranulation without altering the release of newlySince their initial classiﬁcation as a family of multichain recep-
tors involved in immune recognition [1], immunoreceptors have
been recognized as chief regulators of antigen-driven immune re-
sponses [2]. They do so by either activating or inhibiting a series
of secretory responses that participate in cell killing, pro-and
anti-inﬂammatory reactions, cell growth, intercellular communi-
cation etc. Besides the classical antigen receptors on B and T lym-
phocytes this family also includes the family of receptors for the Fc
portion of immunoglobulins (FcR), which are expressed on multi-
ple cell types in the immune system including neutrophils, macro-
phages, mast cells and basophils [3]. Activation of mast cells
through high-afﬁnity IgE receptor (FceRI) and IgE-antigen has been
a paradigm for the study of Fc receptors signaling [4,5]. Aggrega-
tion of FceRI leads to the release of inﬂammatory mediators by
mast cells, some of which, such as proteases, vasoactive amines
and proteoglycans, are stored in cytoplasmic granules and released
through a process of degranulation. Others, such as leukotrienes
(LT) and prostaglandins (PG), are released after de novo synthesis
that do not require activation of gene transcription, whereas cyto-
kines and growth factors are released following transcription of
their genes after mast cell activation [6].chemical Societies. Published by E
niversité Paris 7, Faculté de
Henri Huchard, 75780 Parissynthesized mediators could be of therapeutic interest to block,
for instance, allergy-inducing histamine release without altering
the recruitment of immune competent cells by mast cells through,
for instance, LTB4 or TNFa [4]. Recent progress from our laboratory
shows that such selective control can be obtained through modu-
lation either of early signaling steps or of late degranulation steps.
This short review will focus on these recent advances.
2. Regulation of early signaling steps: a matter of ampliﬁcation
and control ?
Propagation of activation signals within a given cell requires re-
lays acting as signal intermediates that receive information from
upstream and forward it downstream [7]. To be part of the signal-
ing network these signal intermediates must sense changes in their
surroundings such as pH, redox potential, presence of ions (such as
Ca++), or direct interaction with upstream molecular partners. This
change results in covalent modiﬁcation of the signal intermediate
(e.g., through phosphorylation), conformational change and/or
recruitment to a different cell compartment. The relay molecule
that has been modiﬁed can then translate the information received
into a forwarded information by recruitment, dissociation from
and/or modiﬁcation (through enzymatic activity) of downstream
partners, or production of second messenger (again, through enzy-
matic activity). It is not surprising therefore that the ﬁrst so-called
signal effector molecules that have been described were enzymes
among which the most studied are kinases, phosphatases and pro-
teases. It is not surprising also that many signal intermediateslsevier B.V. All rights reserved.
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with a variety of molecular partners [8].
Beside these intermediates that form the framework of the net-
work within which the signal propagates inside the cell, others play
important roles asmodulators. Aswould do a rheostat they increase
or decrease the signal intensity in steps that are downstream their
point of intervention. They have been named ‘‘ampliﬁers” and
‘‘gatekeepers” by some authors depending on their mode of action.
In any case they do not change the quality of the response but alter
it quantitatively. The overall signal output depends therefore both
on the signal framework and on its modulators.
In the FceRI system in mast cells, an example of gatekeeper is
the inositol polyphosphate-5-phosphatase SHIP1 that hydrolyzes
the 50-phosphate of phosphoinositides thereby dampening signal-
ing [9]. On the other hand an example of ampliﬁer is the b chain
of FceRI that acts mainly through anchoring of the Src-family tyro-
sine kinase Lyn to the receptor, thereby facilitating the ﬁrst steps of
signal transduction [10].3. Phospholipid scramblase 1 (PLSCR1) as an ampliﬁer of FceRI
signaling
Recently, we have reported that another protein, the phospho-
lipid scramblase 1 (PLSCR1) may play an ampliﬁer role in
FceRI-dependent signal transduction [11]. PLSCR1 is a mem-
brane-anchored protein that is palmitoylated. We reported that
following FceRI engagement, PLSCR1 is phosphorylated on tyrosine
[12]. Interestingly, the heterogeneous apparent molecular weight
of phosphorylated PLSCR1 strongly suggests that it is modiﬁed
on more than one tyrosine residue and, hence, that it may regulate
and/or be regulated by a number of proteins. In agreement with
this conclusion tyrosine phosphorylation of PLSCR1 in FceRI-stim-
ulated mast cells is regulated at multiple levels. It is strongly phos-
phorylated upon calcium inﬂux [12] and its phosphorylation
induced by FceRI aggregation is signiﬁcantly decreased, but still
observed, in the absence of calcium inﬂux (unpublished observa-
tion). The residual phosphorylation depends on the tyrosine kinase
Lyn with which PLSCR1 interacts. In addition, it appears that the
tyrosine kinase Fyn may regulate negatively PLSCR1 phosphoryla-
tion (unpublished observation). Therefore, tyrosine phosphoryla-
tion of PLSCR1 following FceRI aggregation in mast cells results
from a combined effect of Lyn and calcium mobilization (Fig. 1).
PLSCR1 is known to play multiple roles. In vitro, in reconstituted
proteoliposomes it promotes calcium-dependent and bi-directional
redistribution of phospholipids between the two leaﬂets of the lipid
bilayer [13]. Hence, its name as scramblase since it was originally
thought that PLSCR1 is responsible for the scrambling of phospho-
lipids observed in cells undergoing apoptosis and in some stimu-
lated cells such as platelets and mast cells. Although many
reports conﬁrmed the role of PLSCR1 as a phospholipid scramblase,
this issue is a matter of controversy that remains unsettled since, in
PLSCR1 knock-out mice, phospholipids scrambling is still observed
in platelets [14]. Additional roles for PLSCR1 have been reported.
PLSCR1 contains a non-classical nuclear localization signal and it
can be imported into the nucleus where it interacts with the pro-
moter of the inositol 1,4,5-trisphosphate receptor 1 gene and in-
duces its transcription [15]. This depends on importin a [16] and
is observed when PLSCR1 is not palmitoylated [17]. Other functions
have been reported for this protein. In the EGF receptor system it
associates with this receptor through interaction with the adaptor
Shc and with the tyrosine kinase Src and it increases Src activity
when it is phosphorylated by Src and EGFR [18]. This suggested that
PLSCR1 might play a signal amplifying function.
To address this question we generated RBL-2H3 mast cell
transfectants expressing shRNA speciﬁc for PLSCR1 mRNA [11].These transfectants expressed an extremely low level of the pro-
tein that was decreased to a few percent of the level seen in
untransfected or in control shRNA expressing cells. In the nearly
absence of PLSCR1, degranulation of mast cells was strongly re-
duced. Likewise, production of VEGF was impaired but neither
that of MCP-1 nor that of arachidonic acid metabolites. Of note,
phosphorylation of ERK1/2 that is upstream of PLA2 activation re-
mained unaffected by PLSCR1 knock-down in agreement with the
unaffected production of LT and PG. These observations were a
strong indication that PLSCR1 modulated a selected part of the
signaling network activated by FceRI aggregation. This signaling
network involves two pathways initiated by the Src-family tyro-
sine kinases Lyn and Fyn, respectively [6]. In our study, we ob-
served that steps downstream of Lyn activation were affected by
PLSCR1. These included LAT phosphorylation, PLCc1 phosphoryla-
tion and calcium mobilization (Fig. 1). Yet, phosphorylation of the
b chain of FceRI was not affected suggesting that Lyn itself might
not be the point of the network where PLSCR1 intervenes. We ob-
served that the tyrosine kinase Syk is also associated with PLSCR1.
Modulation of this kinase by PLSCR1, however, should have re-
sulted in a broader phenotype for PLSCR1-knock-down mast cells
since Syk is required for almost every aspect of mast cell re-
sponses to FceRI aggregation. Therefore, the molecular mechanism
allowing PLSCR1 to modulate cell activation remains unfully
resolved.4. The vesicular compartment for secretion in mast cells
While in the past many studies have focused on molecular sig-
naling steps initiated by IgE receptor aggregation, some have
started to analyze the molecular mechanisms involved in the late
events leading to the fusion of mediator-containing vesicular carri-
ers [19]. They involve release of mediators prestored in their
numerous cytoplasmic secretory granules (SGs) as well as the re-
lease of newly synthesized cytokines and chemokines. Targeting
late steps presents the advantage that, in addition to inhibition
of cognate IgE-mediated responses, they may also control the gen-
eral overﬂow of an inﬂammatory reaction that follows activation of
many different receptors.
In contrast to other specialized secretory cells (neurons, exo-
crine and endocrine cells), which have specialized storage organ-
elles, cells of the haematopoietic lineage like mast cells possess
mixed-type SGs or secretory lysosomes connected to the endo-
somal and lysosomal pathway [20]. Their biogenesis in mast cells
is still poorly understood, partly due to their heterogenous nature
with three types of storage organelles (Type I, II, III) being deﬁned
at the ultrastructural level [21]. In addition, they may be subject to
maturation processes during mast cell differentiation in the vari-
ous tissues. Proper storage in these organelles crucially depends
on proteoglycan content as shown in mice with defects in heparin
or serglycine synthesis [22]. Little is known about chemokine/cyto-
kine secretion. While some of them, like for example TNF, can be
released in part from cytoplasmic storage organelles [6], the vesic-
ular carriers for secretion of newly synthesized cytokines/chemo-
kines have not been deﬁned clearly. While they could represent a
constitutive secretory pathway with upregulation of secretion sim-
ply reﬂecting increased new mRNA and protein synthesis, they
may also be routed to intermediate storage compartments that al-
low directional release as evidenced in T cells (synapse) and mac-
rophages (phagocytotic cup) [23]. Against such a simple scenario
speak, however, early studies showing that TNF release is depen-
dent on stimulus/secretion coupling as secretion could be inhibited
by interrupting receptor aggregation with hapten or speciﬁc inhib-
itors under conditions where intracellular TNF levels were still
accumulating [24].
Fig. 1. Secretion by mast cells is modulated by PLSCR1 through ampliﬁcation of the LAT/PLCc1/calcium axis. PLSCR1 is tyrosine phosphorylated by Lyn (but not Fyn) and upon
calciummobilization in FceRI-dependent signaling. In turn, PLSCR1 ampliﬁes LAT tyrosine phosphorylation and the ensuing LAT/PLCc1/calcium axis leading to degranulation.
This axis is initiated when Syk is recruited to the FceRIc chain after tyrosine phosphorylation of its ITAMmotif by Lyn. After phosphorylation of LAT by Syk, PLCc1 is recruited
to phosphorylated LAT and phosphorylated on tyrosine, leading to its activation. PLCc1 then cleaves phosphatidylinositol into inositol trisphosphate (IP3) and diacylglycerol
(DAG). IP3 binds to receptors on endoplasmic reticulum leading to release of calcium into the cytosol. Emptying calcium intracellular stores activates calcium inﬂux through
ICRAC current after opening of the Orai1 calcium channel by activated Stim1. Both mechanisms result in increase in free cytosolic calcium. Classical PKC activation by DAG and
free cytosolic calcium then impact critically on granule movement leading to mast cell degranulation. The major questions that still stand out regarding PLSCR1 function are
the role of PLSCR1 tyrosine phosphorylation in its function, and how PLSCR1 modulates LAT phosphorylation.
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In membrane trafﬁcking, the fusion of vesicular carriers with
the plasma membrane (PM) or with other vesicular carriers re-
quires a conserved molecular machinery of soluble N-ethylmalei-
mide-sensitive factor attachment protein receptors (SNARE)
membrane fusion proteins [25,26]. It is composed of vesicular
SNAREs (v-SNARE) and target t-SNAREs (t-SNAREs) that lie, respec-
tively on opposing donor and acceptor membranes. They favour
the merger of lipid bilayers by forming a tight tetrameric complex
(composed of one v-SNARE and either two or three t-SNAREs)
through sequences of about 60 aa known as SNARE motif. Its disas-
sembly requires binding to soluble NSF attachment proteins
(SNAPs) that bridge the interaction to the ATPase N-ethylmalei-
mide-sensitive factor (NSF). This SNARE cycle (Fig. 2) is controlled
by an array of regulatory factors, which include Sec1/Munc18-,
Munc13-, Rab-, complexin- and Synaptotagmin-family members
[25,26]. Together, they are responsible for the priming, tethering
and docking to assure speciﬁcity of the fusion process. They also al-
low to refrain storage organelles from fusion and to connect the fu-
sion machinery to receptor stimulation. Thus, in a manner similar
to the early signaling events described above, some of the acces-
sory proteins have a function as gatekeepers or ‘‘fusion clamps”
to limit fusion probability. Others function as ampliﬁers to increase
either the speed or the extent of the fusion reaction. The fusion
machinery is closely linked to other regulatory systems such as
the cytoskeleton, which may complement its action for example
by restricting the access of SGs to the plasma membrane (PM) orby positive interactions to support granule transport and fusion
during exocytosis [6].
Treatment of mast cells with the NSF-inactivating compound
N-ethylmaleimide (NEM) or transfection of a dominant-negative
a-SNAP unable to activate the ATPase dramatically inhibits
degranulation clearly pointing to a SNARE-mediated process
[27,28]. Work from several laboratories has allowed to deﬁne a
ﬁrst functional SNARE complex implicated in granule exocytosis
following IgE-mediated triggering composed of the granule-local-
ized v-SNARE protein VAMP8 and the t-SNAREs Syntaxin4 and
SNAP-23 (Fig. 2). In addition, lysosomal VAMP proteins (VAMP7)
or granule-localized Syntaxin3 may also play a role [27,29]. This
is consistent with the heterogeneity of the granular compartment
in mast cells and the fact that these cells, besides undergoing
granule–plasma membrane fusion, also show multiple granule–
granule fusion events that may occur in a successive manner
from the periphery to the interior (compound exocytosis). The
ﬁrst SNARE protein to be identiﬁed was the PM-localized t-SNARE
SNAP-23 [30]. Introduction of a blocking antibody into rat perito-
neal mast cells blocked either calcium or GTPcS-induced degran-
ulation. Similar data were recently obtained in FceRI-stimulated
primary human mast cells [29]. During degranulation, SNAP-23
redistributes from the PM to form degranulation channels, which
may be one particularity of the compound exocytosis process ob-
served in mast cells [30]. Interestingly, after stimulating mast cell
exocytosis, the amount of ternary SNARE complexes containing
SNAP-23 in raft domains was increased [31]. Furthermore,
phosphorylated SNAP-23 was exclusively present within these
Fig. 2. Secretion by mast cells involves the SNARE machinery of membrane fusion. In resting cells SNARE-mediated membrane fusion is blocked, likely by multiple
gatekeepers that include Rak3D and Munc18-2. Stimulation through FceRI initiates signaling events that favour the formation of a stable multi-molecular Trans-SNARE
complex that drives fusion and coordinate the interaction with cytoskeletal elements. A basic functional complex involved in secretion of preformed mediator is composed of
the granule-localized v-SNARE VAMP8 and the plasma membrane-associated Syntaxin4 and SNAP-23 t-SNAREs. In addition granule-localized Syntaxin 3 and relocated SNAP-
23 may play a role in granule–granule fusion observed in mast cells. Complex formation is, in addition, regulated by the activation of multiple accessory proteins such as
Munc18-2, Synaptotagmin II, Complexin, SCAMP, Doc2a, Rab27b and Munc13-4 that allow to relieve the fusion clamps and to amplify the fusion reaction. After fusion the
SNARE complex is disassembled in an energy requiring process that requires binding of the ATPase NSF via SNAP adaptor proteins.
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naling events induced by FceRI stimulation. Similarly, overexpres-
sion of Syntaxin4 negatively regulated exocytosis and enhanced
amounts of SNAP-23/Syntaxin4 were found in raft domains after
degranulation [31,32]. In human mast cells introduction of anti-
Syntaxin4 also blocked FceRI-induced histamine release [29].
Concerning granule-localized v-SNAREs, at present convincing
evidence exists for a role of VAMP8. In various mast cell types,
VAMP8 was found to partially co-localize with the SG markers,
serotonin and mMCP-6 (tryptase) [33]. Partial colocalization
may be explained by the fact that it is also known to localize
to endosomes [34], further supporting the close connection with
the secretory compartment in mast cells. Upon stimulation
VAMP8 translocates to the PM, and increased amounts of com-
plexes with Syntaxin4 and SNAP-23 can be detected [33]. Fur-
thermore, bone marrow derived mast cells (BMMC) from
VAMP8-deﬁcient mice exhibited a reduced degranulation and
mice had decreased histamine levels in passive systemic anaphy-
laxis experiments. The role of VAMP8 was conﬁrmed in the RBL-
2H3 rat mast cell line and in human mast cells [28,29]. Another
study using VAMP8-deﬁcient BMMC suggested that VAMP8 may
further discriminate between granule subpopulations, as it may
control the release of serotonin, cathepsin-D, and b-hexosamini-
dase but not of histamine, which may localize to distinct SGs
[35]. However, such differential release was not seen in the other
reports.Some of these studies also addressed a possible role of VAMP8
in cytokine secretion [33,35]. Absence of VAMP8 did not affect
the secretion of newly synthesized cytokines such as TNF, IL6,
MIP-1a or IL4 suggesting that these cytokines are routed through
a different vesicular carrier compartment. Interestingly, when
TNF secretion was blocked with TNF-alpha-converting enzyme
(TACE) inhibitor TAPI-1, which prevents cleavage of its mem-
brane-bound precursor, TNF accumulated at the PM, where it
showed a strong overlap with a VAMP3-containing compartment
[33]. As VAMP3 has previously been associated with the endocy-
totic recycling compartment, this could indicate interception with
a constitutive intracellular trafﬁcking pathway. However, this has
not yet been conﬁrmed in functional studies.
6. FceRI signaling and membrane fusion
It has been recognized for long that the increase in intracellular
calcium levels and the activation of protein kinase C constitute cru-
cial molecular events that enable exocytosis of cytoplasmic gran-
ules [6]. However, one is now only beginning to identify some of
the molecular targets of their action. Furthermore it has become
clear that in addition to calcium and PKC, other mechanisms of ac-
tion play a role in the fusion process, notably by directly modifying
proteins of the membrane fusion machinery. Emerges a scenario
showing that coordination of several mechanisms are required
for relieving the fusion block and to amplify fusion-promoting
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mechanisms that connect early FceRI signaling to the fusion
machinery. They are also depicted in Fig. 2.
Several effectors molecules have been described that connect
the fusion apparatus to Ca++ signaling. Members of the Synaptotag-
min (Syt) family of single transmembrane proteins are prime can-
didates for being involved in calcium-dependent regulation of
exocytosis. Ca++-binding to the tandem C2 domains (termed C2A
and C2B) promotes oligomerization and membrane phospholipid
binding. It also promotes binding to the SNARE complex, allowing
the formation of a quaternary SNARE-Synaptotagmin-Ca++-
phospholipid (SSCAP) complex [25,26]. The simultaneous
phospholipid binding could aid to drive the merger of lipid bilay-
ers, thereby connecting the basic fusion machinery to Ca++-trig-
gered exocytosis. Recently, SynaptotagminII has been described
as the relevant Ca++ sensor of this system in mast cells. In mast
cells SynaptotagminII has perigranular localization. BMMC derived
from SytII-deﬁcient mice showed a severe defect in both lysosomal
b-hexosaminidase and histamine release and conferred to these
mice a strongly decreased passive cutaneous anaphylaxis reaction
[36]. Although in addition to SynaptotagminII, other Synaptotag-
min isoforms are expressed in mast cells, they do not seem to be
directly involved in the fusion process [37]. SynaptotagminII may
act in concert with ComplexinII, a protein that binds to assembled
SNARE complexes and that has been described in neurons to func-
tion as a fusion clamp. However, data from knock-out mice also
support a positive action on exocytosis involving sequences adja-
cent to the SNARE-complex-binding domain. It seems that its
interaction with the SNARE complex generates a metastable state
that serves as a substrate for Synaptotagmin following Ca++-inﬂux
with the induced rearrangement and cooperative interactions pro-
moting fusion. [25,26]. Mast cells were shown to express the Com-
plexinII isoform [38]. Following stimulation ComplexinII relocates
from the cytoplasm to the PM. Knock-down by siRNA markedly
suppressed IgE-induced degranulation and decreased the sensitiv-
ity for Ca++. Although the interaction with Synaptotagmins has not
been addressed, these studies are in agreement with a positive ac-
tion of ComplexinII in the fusion process. Doc2 family members
may also serve as calcium signal relays in mast cells. Like Synapt-
otagmins, these adaptors contain tandem calcium-binding C2A and
C2B domains. They exhibit calcium-dependent phospholipid bind-
ing activity in their calcium-binding C2A domain, which is thought
to be important for regulated exocytosis. Mast cells were shown to
endogenously express the Doc2a isoform originally thought to be
neuronal-speciﬁc, while the more ubiquitously Doc2b isoform
was not expressed [39]. It was localized to SGs and can form a tri-
partite complex with Munc13-4 and Rab27, two effectors known,
respectively, to play a role in vesicle priming and regulation of
transition from microtubule to actin-based motility during exocy-
tosis [40,41]. Doc2a-deﬁcient mast cells showed a marked defect
in degranulation underlining the role of this adaptor as a relay
for Ca++-mediated signaling likely acting in concert with the other
effector proteins. Another possible Ca++-dependent process in-
volves a kinase activity detected in immunoprecipitates of the
granule-localized small G protein Rab3D that has a possible role
in fusion [42–44]. This kinase called Rak3D (from Rab3D-associ-
ated kinase) was able to phosphorylate Syntaxin4, but not Syn-
taxin2 and 3 in its N-terminus, which prevented binding of the
SNARE partner SNAP-23. Interestingly, the association with Rab3D
was maximal in resting cells and decreased upon stimulation in a
calcium-dependent manner. Although the identity of this kinase
is not known, this suggests that Rak3D is a calcium-regulated gate-
keeper in stimulus/secretion coupling.
In mast cells activation of protein kinase C (PKC) represents an
essential signal for secretion [6]. Previous studies showed that in
the absence of the calcium-dependent isoform, PKCb secretionwas markedly reduced [45]. Interestingly absence of the calcium-
independent isoform PKCd actually led to enhanced exocytosis
suggesting that it may negatively regulate the fusion process
[46]. Despite the importance of PKC the connection to the fusion
machinery in mast cells is still rather obscure. A possible target
represents myosin light and heavy chains, which are necessary
for the reorganization of the actino-myosin cortex during secretion
[47]. Some information may come from other hematopoietic cells.
Thus, in platelets it was shown that physiologic stimulation with
thrombin led to phosphorylation of Syntaxin4 by PKC, which in
consequence inhibited interaction with its SNARE partner SNAP-
23 [48]. As PKC was required for secretion, the authors concluded
that PKC may represent a necessary step in SNARE complex disas-
sembly. PKC activation in platelets also led to phosphorylation of
Munc18-3, another essential effector of the fusion machinery
[49]. This reduced its afﬁnity for Syntaxin2 and Syntaxin4 in plate-
lets. It is possible that this step plays a role in the proposed transi-
tion of Munc18-binding from the closed conformation of Syntaxin
SNARE complex-binding [25]
More recently, another interesting connection was reported by
Suzuki and Verma [50] implicating IjB kinase (IKK) usually known
to regulate the phosphorylation of IjB, which induces nuclear
translocation of the NF-jB transcription factor. In mast cells they
found that IKK transiently phosphorylates a fraction (10%) of
SNAP-23 during degranulation on Ser95/Ser120 within its cys-
teine-rich linker region. Furthermore analysis of IKK-deﬁcient mast
cells revealed that they have impaired degranulation and anaphy-
lactic responses when reconstituted into MC-deﬁcient mice. In
these cells, SNAP-23 formed fewer complexes with Syntaxin4,
VAMP2 and VAMP8 in rafts, suggesting that SNAP-23 phosphoryla-
tion is required for complex formation. This is also supported by
the ﬁnding that it is the phosphorylated form of SNAP-23 that pref-
erentially accumulated in lipid rafts known to be the sites of fusion
[31,51]. In vivo, IKK phosphorylated residues Ser95/Ser120 and
reconstitution with phosphorylation-mimetic mutant into IKK-
deﬁcient MCs partially restored, while over-expression of phos-
phorylation mutants inhibited, IgE-stimulated exocytosis.
Another type of effector that may connect to FceRI signaling to
regulate fusion are secretory carrier membrane proteins (SCAMPs),
a family of ubiquitous membrane proteins of transport vesicles.
They are highly expressed in various cell types on organelles
undergoing regulated exocytosis including mast cell SGs [52]. They
are molecules with four transmembrane domains (tetraspanins)
with the short segment (E peptide) linking the second and third
TM domain being the most highly conserved element and unique
to SCAMPs [52,53]. Mast cells express three SCAMP isoforms, with
SCAMP1 and SCAMP2 being most highly expressed [52,53]. Besides
on SGs they are also found at the PM co-localizing with Syntaxin4
and SNAP-23. Introduction of the E-peptide interfered with degran-
ulation in permeabilized MCs. SCAMPs seem to act at the ﬁnal
fusion step subsequent to SNAP-23 relocation and ATP-dependent
priming in agreement with data showing that genetic deﬁciency
of SCAMP2 causes an apparent defect in forming stable fusion pores
[52]. SCAMPs may act at a step that couples Arf6-stimulated
phospholipase D (PLD) activity to formation of fusion pores, as
the peptide also inhibits PLD activity [52]. This could be in agree-
ment with the proposed coupling of PLD in MC exocytosis [54].7. Sec1/Munc18 (SM) proteins as regulators of SNARE complex
formation
Besides cognate SNARE proteins, Sec1/Munc18 (SM) family
members have been described to represent essential proteins in
the fusion process [25,26]. More particularly, Munc18 proteins
are involved in the regulation of exocytosis. Besides, the neuronal
Table 1
Effectors of stimulus/secretion coupling by FceRI.
Effector Role in stimulus secretion coupling by FceRI References
SNAP-23 Essential t-SNARE at the PM, role in SG-PM fusion [30,31]
Syntaxin4 Essential t-SNARE at the PM, role in SG-PM fusion [30–32]
Syntaxin3 t-SNARE on SGs, possible role in SG-PM fusion? [27]
VAMP8 v-SNARE on SGs, role in SG-PM fusion [28,29,33,35]
VAMP7 Essential v-SNARE on SGs, role in SG-PM fusion [29]
SynaptotagminII Ca++ sensor on SGs, enables coupling of the SNARE fusion machinery to Ca++ [36]
ComplexinII SNARE complex-binding protein, can act as a fusion clamp, in mast cells it may coordinately act with Synaptotagmin to couple
the SNARE fusion machinery to Ca++
[38]
Doc2a Ca++ sensor on SGs, Ca++ sensor that may act in a tripartite complex with the fusion regulators Munc13-4 and Rab27 [39]
Rak3D Rab3D-associated kinase, phosphorylates Syntaxin4thereby blocking interaction with the SNAP-23 SNARE partner [43]
Protein kinase C Essential fusion regulator, absence of PKCb decreases fusion, absence of PKCd enhances fusion, may act by phosphorylating fusion
proteins and regulators (Syntaxin4 and Munc18)
[45,46,48,49,60]
IjB kinase (IKK) Upstream regulator of SNAP-23, phosphorylation of SNAP-23 is necessary for fusion [50]
PLSCR1 Signaling effector with amplifying function of the LAT/PLCc1/Ca++ axis [11,12]
SCAMPs Effectors of the late steps in fusion, stabilization of fusion pores, couples to Arf6-stimulated PLD [52,53]
Munc18-2 Essential fusion accessory protein, may promote fusion through interaction with microtubules [55,56]
Munc13-4 Essential fusion accessory protein, may play a role in fusion priming together with Rab27 [40]
Rab27b Fusion effector, interacts with Munc13-4 and Doc2a, may function by connecting to the cytoskeleton [41]
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and Munc18-3 isoforms have been described. They also are found
to be expressed in mast cells [55–57]. Each Munc18 isoform binds
to a distinct set of Syntaxin proteins withMunc18-2 binding to Syn-
taxin2 and 3, while Munc18-3 binds to Syntaxin2 and Syntaxin4
[25,26,55]. Given that Syntaxin proteins constitute a much larger
family of proteins, it is possible that Munc18-binding Syntaxin iso-
forms fulﬁl speciﬁc functions in regulated exocytosis. The action of
Munc18 proteins is coupled to their modes of interaction with cog-
nate SNARE proteins to promote the fusion reaction. While interac-
tion with the ‘‘closed” uncomplexed conformation of Syntaxin
prevents the interaction with other SNARE proteins and may have
gatekeeping functions [58], stimulation promotes a conformational
rearrangement that favours binding to the assembled SNARE com-
plex and fusion [25,26]. Interestingly, this binding takes place at the
C-terminal end close to the membrane suggesting that Munc18
may aid the force transfer during fusion [59]. It should be noted that
phosphorylation by PKC prevents binding to the closed conforma-
tion [60]. Furthermore, experimental evidences suggest that
Munc18 proteins may have additional functions that include the
steps leading to vesicle translocation, tethering and docking, which
may not necessarily relate to SNARE binding but could involve the
interaction with other effectors [25]. In mast cells, previous
functional studies have demonstrated a role for SG-localized
Munc18-2 [55,57], while so far no function has been described for
PM-localized Munc18-3, although the latter seems to play a role
in neutrophil exocytosis [61].
In mast cells, Munc18-2 redistributed into forming lamellipodia
and persisted on granules that were aligned along microtubules,
but was excluded from F-actin rufﬂes. Disruption of the microtu-
bule network with nocodazole provoked Munc18-2 redistribution
and affected mediator release [55]. This suggested that in mast
cells Munc18-2 action could be coupled to microtubule network
during secretion. Recent data obtained in patients carrying muta-
tions in Munc18-2 have conﬁrmed the important role of this iso-
form in regulated secretion by hematopoietic cells. Indeed, the
deﬁciency in expression and stability of Munc18-2 led to a conse-
quent secondary downregulation of Syntaxin11 causing familial
hemophagocytic lymphohistiocytosis type 5 (FHL-5) impairing ly-
tic granule exocytosis in natural killer and cytotoxic T cells [62,63].
8. Concluding remarks and future directions
It has now become apparent that triggering of FceRI in mast
cells engages a complex signaling network that couples to a sophis-ticated machinery of secretion. It is characterized by numerous
essential effectors required for the signaling to function, but also
by a series of molecules that regulate the system either to dampen
the process (gatekeepers and fusion clamps) or to amplify the reac-
tion to increase the extent and/or speed of the ﬁnal secretory
event. They are summarized in Table 1. Although the identiﬁcation
of some of these connections has allowed to enhance our under-
standing of the involved effectors and mechanisms, many major
questions remain unresolved. For example, little is still known
about the mechanisms enabling the secretion of the numerous
cytokines and chemokines released by mast cells. Furthermore
the connections of the fusion machinery with the cytoskeleton
need to be further deﬁned.
Modulation of the signals controlling mediators release by mast
cells has therapeutic potentials. Indeed, mast cells play a number
of functions that are either deleterious or protective depending
on the context of their activation. For instance it is well known that
mast cells are critically involved in allergic reactions whereas their
positive role as sentinels against infection or in tissue repair mech-
anisms is well demonstrated [64–66]. These various roles are
played mainly through the release of an array of mediators. The
selective modulation of mast cell degranulation by PLSCR1 or
VAMP8 represents therefore an opportunity for the development
of therapeutic drugs targeting deleterious aspects of mast cell biol-
ogy without abolishing all of its important physiologic functions.
Acknowledgements
We apologize to the colleagues, whose work could not be cited.
Work in our group was funded in part by Grants from Inserm, the
French National Research Agency (R08171HS), the ‘‘Fondation pour
la Recherche Médicale” (FRM), the Ligue Nationale Contre le
Cancer, and by the ‘‘Association pour l’Utilisation du Rein Artiﬁciel”
(AURA).
References
[1] Keegan, A.D. and Paul, W.E. (1992) Multichain immune recognition receptors:
similarities in structure and signaling pathways. Immunol. Today 13, 63–68.
[2] Blank, U., Launay, P., Benhamou, M. and Monteiro, R.C. (2009) Inhibitory ITAMs
as novel regulators of immunity. Immunol. Rev. 232, 59–71.
[3] Nimmerjahn, F. and Ravetch, J.V. (2007) Fc-receptors as regulators of
immunity. Adv. Immunol. 96, 179–204.
[4] Kinet, J.P. (1999) The high-afﬁnity IgE receptor (Fc epsilon RI): from physiology
to pathology. Annu. Rev. Immunol. 17, 931–972.
[5] Marchand, F., Mecheri, S., Guilloux, L., Iannascoli, B., Weyer, A. and Blank, U.
(2003) Human serum IgE-mediated mast cell degranulation shows poor
correlation to allergen-speciﬁc IgE content. Allergy 58, 1037–1043.
M. Benhamou, U. Blank / FEBS Letters 584 (2010) 4941–4948 4947[6] Blank, U. and Rivera, J. (2004) The ins and outs of IgE-dependent mast-cell
exocytosis. Trends Immunol. 25, 266–273.
[7] Fraser, I.D. and Germain, R.N. (2009) Navigating the network: signaling cross-
talk in hematopoietic cells. Nat. Immunol. 10, 327–331.
[8] Rivera, J. (2002) Molecular adapters in Fc(epsilon)RI signaling and the allergic
response. Curr. Opin. Immunol. 14, 688–693.
[9] Huber, M., Helgason, C.D., Damen, J.E., Liu, L., Humphries, R.K. and Krystal, G.
(1998) The src homology 2-containing inositol phosphatase (SHIP) is the
gatekeeper of mast cell degranulation. Proc. Natl. Acad. Sci. USA 95, 11330–
11335.
[10] Lin, S., Cicala, C., Scharenberg, A.M. and Kinet, J.P. (1996) The Fc(epsilon)RIbeta
subunit functions as an ampliﬁer of Fc(epsilon)RIgamma-mediated cell
activation signals. Cell 85, 985–995.
[11] Amir-Moazami, O., Alexia, C., Charles, N., Launay, P., Monteiro, R.C. and
Benhamou, M. (2008) Phospholipid scramblase 1 modulates a selected set of
IgE receptor-mediated mast cell responses through LAT-dependent pathway. J.
Biol. Chem. 283, 25514–25523.
[12] Pastorelli, C., Veiga, J., Charles, N., Voignier, E., Moussu, H., Monteiro, R.C. and
Benhamou, M. (2001) IgE receptor type I-dependent tyrosine phosphorylation
of phospholipid scramblase. J. Biol. Chem. 276, 20407–20412.
[13] Zhou, Q., Zhao, J., Stout, J.G., Luhm, R.A., Wiedmer, T. and Sims, P.J. (1997)
Molecular cloning of human plasma membrane phospholipid scramblase. A
proteinmediating transbilayermovement of plasmamembrane phospholipids.
J. Biol. Chem. 272, 18240–18244.
[14] Zhou, Q., Zhao, J., Wiedmer, T. and Sims, P.J. (2002) Normal hemostasis but
defective hematopoietic response to growth factors in mice deﬁcient in
phospholipid scramblase 1. Blood 99, 4030–4038.
[15] Zhou, Q., Ben-Efraim, I., Bigcas, J.L., Junqueira, D., Wiedmer, T. and Sims, P.J.
(2005) Phospholipid scramblase 1 binds to the promoter region of the inositol
1, 4, 5-triphosphate receptor type 1 gene to enhance its expression. J. Biol.
Chem. 280, 35062–35068.
[16] Chen, M.H., Ben-Efraim, I., Mitrousis, G., Walker-Kopp, N., Sims, P.J. and
Cingolani, G. (2005) Phospholipid scramblase 1 contains a nonclassical nuclear
localization signal with unique binding site in importin alpha. J. Biol. Chem.
280, 10599–10606.
[17] Wiedmer, T., Zhao, J., Nanjundan, M. and Sims, P.J. (2003) Palmitoylation of
phospholipid scramblase 1 controls its distribution between nucleus and
plasma membrane. Biochemistry 42, 1227–1233.
[18] Nanjundan, M., Sun, J., Zhao, J., Zhou, Q., Sims, P.J. and Wiedmer, T. (2003)
Plasma membrane phospholipid scramblase 1 promotes EGF-dependent
activation of c-Src through the epidermal growth factor receptor. J. Biol.
Chem. 278, 37413–37418.
[19] Blank, U., Cyprien, B., Martin-Verdeaux, S., Paumet, F., Pombo, I., Rivera, J., Roa,
M. and Varin-Blank, N. (2002) SNAREs and associated regulators in the control
of exocytosis in the RBL-2H3 mast cell line. Mol. Immunol. 38, 1341–1345.
[20] Benado, A., Nasagi-Atiya, Y. and Sagi-Eisenberg, R. (2009) Protein trafﬁcking in
immune cells. Immunobiology 214, 403–421.
[21] Raposo, G., Tenza, D., Mecheri, S., Peronet, R., Bonnerot, C. and Desaymard, C.
(1997) Accumulation of major histocompatibility complex class II molecules
in mast cell secretory granules and their release upon degranulation. Mol. Biol.
Cell. 8, 2631–2645.
[22] Pejler, G., Abrink, M., Ringvall, M. and Wernersson, S. (2007) Mast cell
proteases. Adv. Immunol. 95, 167–255.
[23] Stow, J.L., Ching Low, P., Offenhauser, C. and Sangermani, D. (2009) Cytokine
secretion in macrophages and other cells: pathways and mediators.
Immunobiology 214, 601–612.
[24] Baumgartner, R.A., Yamada, K., Deramo, V.A. and Beaven, M.A. (1994)
Secretion of TNF from a rat mast cell line is a brefeldin A-sensitive and a
calcium/protein kinase C-regulated process. J. Immunol. 153, 2609–2617.
[25] Sudhof, T.C. and Rothman, J.E. (2009) Membrane fusion: grappling with SNARE
and SM proteins. Science 323, 474–477.
[26] Rizo, J. and Rosenmund, C. (2008) Synaptic vesicle fusion. Nat. Struct. Mol.
Biol. 15, 665–674.
[27] Puri, N., Kruhlak, M.J., Whiteheart, S.W. and Roche, P.A. (2003) Mast cell
degranulation requires N-ethylmaleimide-sensitive factor-mediated SNARE
disassembly. J. Immunol. 171, 5345–5352.
[28] Lippert, U., Ferrari, D.M. and Jahn, R. (2007) Endobrevin/VAMP8 mediates
exocytotic release of hexosaminidase from rat basophilic leukaemia cells.
FEBS Lett. 581, 3479–3484.
[29] Sander, L.E., Frank, S.P., Bolat, S., Blank, U., Galli, T., Bigalke, H., Bischoff, S.C.
and Lorentz, A. (2008) Vesicle associated membrane protein (VAMP)-7 and
VAMP-8, but not VAMP-2 or VAMP-3, are required for activation-induced
degranulation of mature human mast cells. Eur. J. Immunol. 38, 855–863.
[30] Guo, Z., Turner, C. and Castle, D. (1998) Relocation of the t-SNARE SNAP-23
from lamellipodia-like cell surface projections regulates compound exocytosis
in mast cells. Cell 94, 537–548.
[31] Puri, N. and Roche, P.A. (2006) Ternary SNARE complexes are enriched in lipid
rafts during mast cell exocytosis. Trafﬁc 7, 1482–1494.
[32] Paumet, F., Le Mao, J., Martin, S., Galli, T., David, B., Blank, U. and Roa, M. (2000)
Soluble NSF attachment protein receptors (SNAREs) in RBL-2H3 mast cells:
functional role of syntaxin 4 in exocytosis and identiﬁcation of a vesicle-
associated membrane protein 8-containing secretory compartment. J.
Immunol. 164, 5850–5857.
[33] Tiwari, N. et al. (2008) VAMP-8 segregates mast cell-preformed mediator
exocytosis from cytokine trafﬁcking pathways. Blood 111, 3665–3674.[34] Wong, S.H., Zhang, T., Xu, Y., Subramaniam, V.N., Grifﬁths, G. and Hong, W.
(1998) Endobrevin, a novel synaptobrevin/VAMP-like protein preferentially
associated with the early endosome. Mol. Biol. Cell. 9, 1549–1563.
[35] Puri, N. and Roche, P.A. (2008) Mast cells possess distinct secretory granule
subsets whose exocytosis is regulated by different SNARE isoforms. Proc. Natl.
Acad. Sci. USA 105, 2580–2585.
[36] Melicoff, E. et al. (2009) Synaptotagmin-2 controls regulated exocytosis but
not other secretory responses of mast cells. J. Biol. Chem. 284, 19445–19451.
[37] Sagi-Eisenberg, R. (2007) The mast cell: where endocytosis and regulated
exocytosis meet. Immunol. Rev. 217, 292–303.
[38] Tadokoro, S., Nakanishi, M. and Hirashima, N. (2005) Complexin II facilitates
exocytotic release in mast cells by enhancing Ca2+ sensitivity of the fusion
process. J. Cell. Sci. 118, 2239–2246.
[39] Higashio, H., Nishimura, N., Ishizaki, H., Miyoshi, J., Orita, S., Sakane, A. and
Sasaki, T. (2008) Doc2 alpha and Munc13-4 regulate Ca(2+) -dependent
secretory lysosome exocytosis in mast cells. J. Immunol. 180, 4774–4784.
[40] Neeft, M. et al. (2005) Munc13-4 is an effector of rab27a and controls secretion
of lysosomes in hematopoietic cells. Mol. Biol. Cell. 16, 731–741.
[41] Mizuno, K., Tolmachova, T., Ushakov, D.S., Romao, M., Abrink, M., Ferenczi,
M.A., Raposo, G. and Seabra, M.C. (2007) Rab27b regulates mast cell granule
dynamics and secretion. Trafﬁc 8, 883–892.
[42] Roa, M., Paumet, F., Lemao, J., David, B. and Blank, U. (1997) Involvement of the
ras-like GTPase rab3d in RBL-2H3 mast cell exocytosis following stimulation
via high afﬁnity IgE receptors (Fc epsilon RI). J. Immunol. 159, 2815–2823.
[43] Pombo, I., Martin-Verdeaux, S., Iannascoli, B., Le Mao, J., Deriano, L., Rivera, J.
and Blank, U. (2001) IgE receptor type I-dependent regulation of a Rab3D-
associated kinase. A possible link in the calcium-dependent assembly of
SNARE complexes. J. Biol. Chem. 12, 12.
[44] Coppola, T., Perret-Menoud, V., Gattesco, S., Magnin, S., Pombo, I., Blank, U. and
Regazzi, R. (2002) The death domain of Rab3 guanine nucleotide exchange
protein in GDP/GTP exchange activity in living cells. Biochem. J. 362, 273–279.
[45] Nechushtan, H., Leitges, M., Cohen, C., Kay, G. and Razin, E. (2000) Inhibition of
degranulation and interleukin-6 production in mast cells derived from mice
deﬁcient in protein kinase Cbeta. Blood 95, 1752–1757.
[46] Leitges, M., Gimborn, K., Elis, W., Kalesnikoff, J., Hughes, M.R., Krystal, G. and
Huber, M. (2002) Protein kinase C-delta is a negative regulator of antigen-
induced mast cell degranulation. Mol. Cell. Biol. 22, 3970–3980.
[47] Ludowyke, R., Kawasugi, K. and French, P. (1994) PMA and calcium ionophore
induce myosin and F-actin rearrangement during histamine secretion from
RBL-2H3 cells. Cell Motil. Cytoskeleton 29, 354–365.
[48] Chung, S.H., Polgar, J. and Reed, G.L. (2000) Protein kinase C phosphorylation
of syntaxin 4 in thrombin-activated human platelets. J. Biol. Chem. 275,
25286–25291.
[49] Reed, G.L., Houng, A.K. and Fitzgerald, M.L. (1999) Human platelets contain
SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is
phosphorylated after thrombin activation: implications for platelet secretion.
Blood 93, 2617–2626.
[50] Suzuki, K. and Verma, I.M. (2008) Phosphorylation of SNAP-23 by IkappaB
kinase 2 regulates mast cell degranulation. Cell 134, 485–495.
[51] Lang, T., Bruns, D., Wenzel, D., Riedel, D., Holroyd, P., Thiele, C. and Jahn, R.
(2001) SNAREs are concentrated in cholesterol-dependent clusters that deﬁne
docking and fusion sites for exocytosis. EMJO J. 20, 2202–2213.
[52] Castle, J.D., Guo, Z. and Liu, L. (2002) Function of the t-SNARE SNAP-23 and
secretory carrier membrane proteins (SCAMPs) in exocytosis in mast cells.
Mol. Immunol. 38, 1337–1340.
[53] Guo, Z., Liu, L., Caﬁso, D. and Castle, D. (2002) Perturbation of a very late step
of regulated exocytosis by a secretory carrier membrane protein (SCAMP2)-
derived peptide. J. Biol. Chem. 277, 35357–35363.
[54] Peng, Z. and Beaven, M.A. (2005) An essential role for phospholipase D in the
activation of protein kinase C and degranulation in mast cells. J. Immunol. 174,
5201–5208.
[55] Martin-Verdeaux, S., Pombo, I., Iannascoli, B., Roa, M., Varin-Blank, N., Rivera, J.
and Blank, U. (2003) Analysis of Munc18-2 compartmentation in mast cells
reveals a role for microtubules in granule exocytosis. J. Cell Sci. 116, 325–334.
[56] Pombo, I., Rivera, J. and Blank, U. (2003) Munc18-2/syntaxin3 complexes are
spatially separated from syntaxin3-containing SNARE complexes. FEBS Lett.
550, 144–148.
[57] Tadokoro, S., Kurimoto, T., Nakanishi, M. and Hirashima, N. (2007) Munc18-2
regulates exocytotic membrane fusion positively interacting with syntaxin-3
in RBL-2H3 cells. Mol. Immunol. 44, 3427–3433.
[58] Brandie, F.M., Aran, V., Verma, A., McNew, J.A., Bryant, N.J. and Gould, G.W.
(2008) Negative regulation of syntaxin4/SNAP-23/VAMP2-mediated
membrane fusion by Munc18c in vitro. PLoS ONE 3, e4074.
[59] Carr, C.M. and Rizo, J. (2010) At the junction of SNARE and SM protein
function. Curr. Opin. Cell Biol. 22, 488–495.
[60] Fujita, Y. et al. (1996) Phosphorylation of Munc-18/n-Sec1/rbSec1 by protein
kinase C: its implication in regulating the interaction of Munc-18/n-Sec1/
rbSec1 with syntaxin. J. Biol. Chem. 271, 7265–7268.
[61] Brochetta, C., Vita, F., Tiwari, N., Scandiuzzi, L., Soranzo, M.R., Guerin-
Marchand, C., Zabucchi, G. and Blank, U. (2008) Involvement of Munc18
isoforms in the regulation of granule exocytosis in neutrophils. Biochim.
Biophys. Acta 1783, 1781–1791.
[62] Cote, M. et al. (2009) Munc18-2 deﬁciency causes familial hemophagocytic
lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in
patient NK cells. J. Clin. Invest. 119, 3765–3773.
4948 M. Benhamou, U. Blank / FEBS Letters 584 (2010) 4941–4948[63] zur Stadt, U. et al. (2009) Familial hemophagocytic lymphohistiocytosis type 5
(FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin
11. Am. J. Hum. Genet. 85, 482–492.
[64] Galli, S.J., Grimbaldeston, M. and Tsai, M. (2008) Immunomodulatory mast
cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol.
8, 478–486.[65] Abraham, S.N. and St John, A.L. (2010) Mast cell-orchestrated immunity to
pathogens. Nat. Rev. Immunol. 10, 440–452.
[66] Kanamaru, Y. et al. (2006) Mast cell-mediated remodeling and ﬁbrinolytic
activity protect against fatal glomerulonephritis. J. Immunol. 176, 5607–
5615.
